News and Announcements
Oncosil Medical Investor Presentation August 2016
- Published August 22, 2016 10:17AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
22nd August 2016, ASX Announcement
Overview
- Developing an implantable radiotherapy medical device ‘OncosilTM’ for pancreatic and liver cancer
- CE Mark targeted in the near term followed by commercial launch and sales in UK, EU and Australia
- Technology platform suitable for multiple solid state tumours providing a more targeted therapy
- Global pancreatic cancer market > US1$B
- Global Pivotal Study underway – FDA approved IDE – July, 2016 Trial sites being engaged
- New leadership team – Daniel Kenny CEO (ex Baxter, Roche) and Dr Chris Roberts (ex Cochlear CEO) Chairman-elect
- Proprietary technology with robust patient portfolio
- ASX listed ~ $69m market cap and $13.4m of cash
Device Overview: Radiation therapy delivered directly into the tumour
- Pure “soft beta” radiation source (P32) to avoid systemic side effects
- Localised radiation therapy using “sticky” microparticles
- Carrier particles are inert silicon
- Particles are suspended in fluid to allow direct injection into the tumour
- Single Injection under anesthesia takes 30 minutes
- Local radiation in the tumour lasts around 3 months
To view the full Presentation, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
